Alnylam Pharmaceuticals | ALNY - Cost Of Sales


Alnylam Pharmaceuticals reported $298.45M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Incyte USD 104.96M 457K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Moderna USD 93M 862M Jun/2026
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novartis USD 3.46B 83M Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.14B 618M Mar/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Takeda JPY 517.6B 42.94B Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026
Xencor USD 61.66M 50.95M Jun/2025